The company said the results from the evoke study, which tested an oral semaglutide pill for early-stage symptomatic Alzheimer's disease, were "not what we had hoped for"
A new survey reveals deep scepticism toward AI-generated regulatory materials, with pharma teams citing hallucinations, poor auditability and lack of transparency as major risks
Get breaking news, product releases, technical papers, innovation features, trend reports and live content agendas covering the entire industry.